R Rizzoli1, C-L Benhamou2, J Halse3, P D Miller4, I R Reid5, J A Rodríguez Portales6, C DaSilva7, R Kroon8, N Verbruggen9, A T Leung10, D Gurner7. 1. Division of Bone Diseases, Geneva University Hospitals, CH-1211, Geneva 14, Switzerland. Rene.Rizzoli@unige.ch. 2. Hopital d'Orléans la Source, Orléans, France. 3. Osteoporoseklinikken, Oslo, Norway. 4. Colorado Center for Bone Research, University of Colorado Health Sciences Center, Lakewood, CO, USA. 5. University of Auckland, Auckland, New Zealand. 6. Pontificia Universidad Católica de Chile, Santiago, Chile. 7. Merck & Co., Inc., Kenilworth, NJ, USA. 8. Formerly MSD, Oss, The Netherlands. 9. MSD Europe Inc., Brussels, Belgium. 10. Formerly Merck & Co., Inc., Kenilworth, NJ, USA.
Abstract
UNLABELLED: The efficacy and safety of weekly oral odanacatib (ODN) 50 mg for up to 8 years were assessed in postmenopausal women with low bone mineral density (BMD). Treatment with ODN for up to 8 years resulted in continued or maintained increases in BMD at multiple sites and was well tolerated. INTRODUCTION: ODN is a selective inhibitor of cathepsin K. In a 2-year phase 2b study (3/10/25/50 mg ODN once weekly [QW] or placebo) and extensions (50 mg ODN QW or placebo), ODN treatment for 5 years progressively increased BMD and decreased bone resorption markers in postmenopausal women with low BMD ( ClinicalTrials.gov NCT00112437). METHODS: In this prespecified interim analysis at year 8 of an additional 5-year extension (years 6 to 10), patients (n = 117) received open-label ODN 50 mg QW plus weekly vitamin D3 (5600 IU) and calcium supplementation as needed. Primary end points were lumbar spine BMD and safety. Patients were grouped by ODN exposure duration. RESULTS: Mean (95 % confidence interval [CI]) lumbar spineBMD changes from baseline were 4.6 % (2.4, 6.7; 3-year continuous ODN exposure), 12.9 % (8.1, 17.7; 5 years), 12.8 % (10.0, 15.7; 6 years), and 14.8 % (11.0, 18.6; 8 years). Similar patterns of results were observed for BMD of trochanter, femoral neck, and total hip versus baseline. Geometric mean changes from baseline to year 8 for bone resorption markers were approximately -50 % (uNTx/Cr) and -45 % (sCTx), respectively (all groups); bone formation markers remained near baseline levels. No osteonecrosis of the jaw, delayed fracture union, or morphea-like skin reactions were reported. CONCLUSIONS: Treatment with ODN for up to 8 years resulted in gains in BMD at multiple sites. Bone resorption markers remained reduced, with no significant change observed in bone formation markers. Treatment with ODN for up to 8 years was well tolerated.
RCT Entities:
UNLABELLED: The efficacy and safety of weekly oral odanacatib (ODN) 50 mg for up to 8 years were assessed in postmenopausal women with low bone mineral density (BMD). Treatment with ODN for up to 8 years resulted in continued or maintained increases in BMD at multiple sites and was well tolerated. INTRODUCTION:ODN is a selective inhibitor of cathepsin K. In a 2-year phase 2b study (3/10/25/50 mg ODN once weekly [QW] or placebo) and extensions (50 mg ODN QW or placebo), ODN treatment for 5 years progressively increased BMD and decreased bone resorption markers in postmenopausal women with low BMD ( ClinicalTrials.gov NCT00112437). METHODS: In this prespecified interim analysis at year 8 of an additional 5-year extension (years 6 to 10), patients (n = 117) received open-label ODN 50 mg QW plus weekly vitamin D3 (5600 IU) and calcium supplementation as needed. Primary end points were lumbar spine BMD and safety. Patients were grouped by ODN exposure duration. RESULTS: Mean (95 % confidence interval [CI]) lumbar spine BMD changes from baseline were 4.6 % (2.4, 6.7; 3-year continuous ODN exposure), 12.9 % (8.1, 17.7; 5 years), 12.8 % (10.0, 15.7; 6 years), and 14.8 % (11.0, 18.6; 8 years). Similar patterns of results were observed for BMD of trochanter, femoral neck, and total hip versus baseline. Geometric mean changes from baseline to year 8 for bone resorption markers were approximately -50 % (uNTx/Cr) and -45 % (sCTx), respectively (all groups); bone formation markers remained near baseline levels. No osteonecrosis of the jaw, delayed fracture union, or morphea-like skin reactions were reported. CONCLUSIONS: Treatment with ODN for up to 8 years resulted in gains in BMD at multiple sites. Bone resorption markers remained reduced, with no significant change observed in bone formation markers. Treatment with ODN for up to 8 years was well tolerated.
Entities:
Keywords:
Biochemical markers of bone turnover; Bone mineral density; Cathepsin K inhibition; Clinical trial; Odanacatib; Osteoporosis
Authors: Patricia J Masarachia; Brenda L Pennypacker; Maureen Pickarski; Kevin R Scott; Gregg A Wesolowski; Susan Y Smith; Rani Samadfam; Jason E Goetzmann; Boyd B Scott; Donald B Kimmel; Le T Duong Journal: J Bone Miner Res Date: 2012-03 Impact factor: 6.741
Authors: Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson Journal: J Bone Miner Res Date: 2007-03 Impact factor: 6.741
Authors: Ego Seeman; Pierre D Delmas; David A Hanley; Deborah Sellmeyer; Angela M Cheung; Elizabeth Shane; Ann Kearns; Thierry Thomas; Steven K Boyd; Stephanie Boutroy; Cesar Bogado; Sharmila Majumdar; Michelle Fan; Cesar Libanati; Jose Zanchetta Journal: J Bone Miner Res Date: 2010-08 Impact factor: 6.741
Authors: Michael McClung; Steven T Harris; Paul D Miller; Douglas C Bauer; K Shawn Davison; Larry Dian; David A Hanley; David L Kendler; Chui Kin Yuen; E Michael Lewiecki Journal: Am J Med Date: 2012-11-20 Impact factor: 4.965
Authors: Angela M Cheung; Sharmila Majumdar; Kim Brixen; Roland Chapurlat; Thomas Fuerst; Klaus Engelke; Bernard Dardzinski; Antonio Cabal; Nadia Verbruggen; Shabana Ather; Elizabeth Rosenberg; Anne E de Papp Journal: J Bone Miner Res Date: 2014-08 Impact factor: 6.741
Authors: Brenda L Pennypacker; David Gilberto; Nicholas T Gatto; Rana Samadfam; Susan Y Smith; Donald B Kimmel; Le Thi Duong Journal: J Orthop Res Date: 2015-08-07 Impact factor: 3.494
Authors: Julie A Stone; Jacqueline B McCrea; Rose Witter; Stefan Zajic; S Aubrey Stoch Journal: Br J Clin Pharmacol Date: 2019-03-18 Impact factor: 4.335
Authors: Megan M Weivoda; Chee Kian Chew; David G Monroe; Joshua N Farr; Elizabeth J Atkinson; Jennifer R Geske; Brittany Eckhardt; Brianne Thicke; Ming Ruan; Amanda J Tweed; Louise K McCready; Robert A Rizza; Aleksey Matveyenko; Moustapha Kassem; Thomas Levin Andersen; Adrian Vella; Matthew T Drake; Bart L Clarke; Merry Jo Oursler; Sundeep Khosla Journal: Nat Commun Date: 2020-01-07 Impact factor: 14.919